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The Eaton-Lambert syndrome is a non-metastatic
manifestation of oat-cell carcinoma of the bron-
chus, although it has been reported in patients with
carcinoma at other sites. The clinical picture is
usually on~ of subacute muscular fatiguability with
weakness and wasting affecting the proximal parts
of the limbs and trunk, but occasionally the external
ocular and bulbar muscles are involved. The weak-
ness is often myasthenic, but it has been observed
that muscle power may in fact increase after brief
exercise. The pathogenesis, diagnosis, electro-
physiological features and some aspects of therapy
are reviewed.
S Air Med J 1983; 63: 323-325.
The association of bronchogenic carcinoma with peripheral neu-
ropathies or myasthenia gravis was recognized in the early
1950s. 1 In 1956 Eaton and Lambert2 from the Mayo Clinic
outlined the clinical, pharmacological and electrophysiological
abnormalities in this new syndrome. These authors distin-
guished the syndrome from myasthenia gravis, placed the defect
at the level of the neuromuscular junction, and stressed the
association with malignant neoplasm of the lung.
Clinical features
The main clinical features of the Eaton-Lambert syndrome are:
(i) weakness of proximal limb and girdle muscles; (ii) reduced
rested muscle strength, a temporary increase in strength in
response to voluntary exercise of a few seconds' duration, and
weakness after prolonged physical effort; (iii) decreased or
absent deep tendon reflexes; (iv) associated neoplasms of the
lung in approximately two-thirds of patients; (v) dryness of the
mouth or dysgeusia; (vi) loss of potency, peripheral paraesthesiae
and (very rarely) cerebral ataxia; and (vii) a relatively poor
response to neostigmine and good or very good response to
guanidine, with marked sensitivity to D-tubocurarine.
Weakness in the muscles of the proximal limb and girdle is
usually the initial symptom, giving the patient a feeling of tight-
ness around the hips and shoulders manifested clinically by
difficulty in rising from a chair, climbing stairs or elevating the
arms. Neurological examination usually reveals proximal weak-
ness in all limbs, particularly in the lower limbs. In the early
stages of the disease proximal leg weakness is usually the most
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important neurological finding, and the only subjective com-
plaints may be related to it. Some difficulty in speaking or
swallowing or some temporary double vision may be noted by
about one-third of patients. However, involvement of extra-
ocular, facial and bulbar muscles is not severe. Weakness of the
distal parts of the limbs is also mild and uncommon.
Reduced rested muscle strength, temporarily increased
strength following a few seconds of exercise, and weakness after
prolonged physical effort are other clinical features which distin-
guish the syndrome from myasthenia gravis. On clinical exami-
nation, after a few attempts at voluntary contraction, power of
contraction rises in the muscles that were weak initially, such as
those of the thigh and maybe the shoulder muscles. This is
probably why there is sometimes an apparent discrepancy
between the patient's severe disability and relatively slight weak-
ness on strength testing. Deep tendon reflexes are lessened or
absent, in contrast to the intact deep reflexes in myasthenia
gravis.
Malignant pulmonary tumours are present in about 70% of
patients with the Eaton-Lambert syndrome,3 small-cell carci-
noma of the bronchus being by far the most common associated
tumour.
Loss of potency and peripheral paraesthesiae are other clinical
features of the Eaton-Lambert syndrome, and may be consi-
dered clinical manifestations of 'paraneoplastic neuromyo-
pathy' .
Pharmacological responses in the syndrome are fairly typical;
neostigmine or edrophonium produce at most only slight
improvement in strength, a response quite different from that in
patients with myasthenia gravis, which improves after anticholi-
nergic medication. Guanidine produces only a slight improve-
ment in strength in myasthenia gravis but decided improvement
in the Eaton-Lambert syndrome.
The incidence and prevalence of the syndrome are unknown.
Herrmann4 estimated that the syndrome occurs in slightly less
than I%of cases of primary cancer of the lung. The syndrome is
commoner after the age of 40. Men are four times more fre-
quently affected than women, but this is probably changing
because of the rising incidence of lung cancer in women.
Pathology and" pathogenesis
The most common tumour associated with the Eaton-Lambert
syndrome is the bronchogenic small-cell or oat cell carcinoma,
but other pulmonary tumours such as squamous cell carcinoma
have also been associated with jt. There have been reports of the
syndrome occurring in patients with lymphosarcoma,s Sj6gren's
syndrome6 and sarcoidosis.7
The defect in the Eaton-Lambert syndrome is a functional
block of neuromuscular transmission. In virro intracellular
recordings from intercostal muscle specimens taken from patients
with the syndrome showed that miniature end-plate potentials
produced by an evoked response are diminished. This pheno-
menon may be caused by a decrease in the number of packets of
acetylcholine being released from the nerve terminals with the
nerve impulse. A similar abnormality in neuromuscular trans-
mission is produced by botulism and by neomycin and other
antibiotics. Takamori er al. 8 have postulated that there is a
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defective calcium-dependent acetylcholine release by nerve
impulses that can be partially corrected by calcium and adrena-
line. McQuillen and Johns 9 carried out electrophysiological
studies of the funC1ion of various levels of motor units in the
Eaton-Lambert syndrome and concluded that the basic defect
lies in a dysfunction of neuromuscular transmission and not in
the nerves or muscles. Engel and Santa lO have described an
overdevelopment of the postsynaptic or secondary synaptic
region in the motor end-plate of patients with the syndrome
quite different from that seen in myasthenia gravis.
Diagnosis
The study of the effects of repetitive stimulation of a muscle
through its peripheral nerve is of great assistance in establishing
the diagnosis. The response to a single stimulus is abnormally
small, and if the nerve is stimulated at a slow rate (I - 2 Hz) there
is a progressive reduction in size of the evoked muscle potentials.
On the other hand, with rapid rates of stimulation there is a
progressive increase in the size of the potentials. This pheno-
menon is the electrophysiological translation of the temporary
increase in muscle strength in response to voluntary exercise ofa
few seconds' duration. Single-fibre electromyographic studies
showed an increase in 'jirrer' impulse blocking and improvement
of neuromuscular transmission with high rates of innervation
frequency. This method, however, provides little additional
information for the diagnosis of the syndrome compared with the
regular recording of compound muscle action potentials at dif-
ferent stimulus frequencies.
Muscle biopsy is not diagnostic of the syndrome as it shows
atrophy of type II muscle fibres.
Differential diagnosis
The syndrome should be differentiated from myasthenia gravis
clinically and electrophysiologically (Table I). Myasthenic syn-
dromes associated with antibiotic administration have been
reported, the first reported being neomycin. Myasthenic syn-
dromes have also been reported in hypo- and hyperthyroidism,
acute leukaemia, lupus erythematosus and the use of trimethadi-
one. All these syndromes respond to discontinuation ofthe drugs
that induce them or to treatment of the underlying di5ease
causing the myasthenic condition.
Treatment
The first aim in the treatment of the syndrome is detection ofany
underlying malignant lesion. In some patients symptoms improve
after treatment of the carcinoma, while in others weakness is not
relieved by these measures. Anticholinesterase medication pro-
vides mild or no improvement of strength. Guanidine hydro-
chloride was initially found to be helpful in the treatment of
mysthenia gravis and has subsequently been recognized-as the
drug of choice in the Eaton-Lambert syndrome. It has a good
influence on the fatigue and weakness of patients with the syn-
drome, and the characteristic electrophysiological findings are
significantly improved. The daily dose varies from 20 to 30
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mglkg body weight, given in di.vidend doses. Unfortunately the
drug causes several serious side-effects such as atrial fibrillation,
bone marrow depression, renal tubular necrosis and liver toxi-
city. Germine-3-acetate has been tried with some success, but its
association with numerous sensory symptoms has led to its
discontinuation.
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Summary
An anomalous left coronary artery from the pulmo-
nary artery was diagnosed clinically in 12 patients
(and confirmed angiographically in 11 and at
autopsy in 1). A classic history of 'infantile angina'
was obtained in only 1 patient, while the typical
electrocardiographic findings Of anterolateral
ischaemia or infarction were present in 11 patients
(92%). The majority had evidence of left ventricular
dysfunction _and mitral regurgitation.
Three patients underwent surgical reimplantation
of the anomalous left coronary artery' into the
ascending aorta. Two survive, but with persistent
electrocardiographic changes and cardiomegaly.
Nine patients, of whom 4 survive, were managed
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medically. Five of the 6 deaths occurred within 1
month of diagnosis.
A conservative approach to surgical intervention
is recommended, as surgery is unlikely to alter the
ultimate prognosis.
S AIr Med J 1983: 63: 325-327.
Anomalous origin of the left coronary artery from the pulmonary
artery is an unusual congenital anomaly found in 1/300000
children in the general population.' The condition carries a grave
prognosis with high mortality, especially in the first year of life,
mortality rates of up to 85% being reported.2- 4
The dilemma of whom to recommend for surgery and when
led us to review our experience of this anomaly over the past 10
years. During this period (1970-1979) 12 cases were identified
and details of these together with a review of aspects of the
published data are presented.
Patients
There were 9 females and 3 males. In 11 the clinical diagnosis
was confirmed angiographically, while in the remaining infant it
was confirmed at autopsy. Age at presentation ranged from 5
weeks to 20 months (mean 10 months) excluding a child with a
